Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More
